Predictive value of ex vivo biodynamic imaging in determining response to chemotherapy in dogs with spontaneous non-Hodgkin's lymphomas: a preliminary study.

Biodynamic imaging (BDI) is a novel phenotypic cancer profiling technology which optically characterizes changes in subcellular motion within living tumor tissue samples in response to ex vivo treatment with cancer chemotherapy drugs. The purpose of this preliminary study was to assess the ability of ex vivo BDI to predict in vivo clinical response to chemotherapy in ten dogs with naturally-occurring non-Hodgkin's lymphomas. Pre-treatment tumor biopsy samples were obtained from all dogs and treated ex vivo with doxorubicin (10 μM). BDI measured six dynamic biomarkers of subcellular motion from all biopsy samples at baseline and at regular intervals for 9 h following drug application. All dogs subsequently received doxorubicin to treat their lymphomas. Best overall response to and progression-free survival time following chemotherapy were recorded for all dogs. Receiver operating characteristic (ROC) curves were used to determine accuracy and identify possible cut-off values for the BDI-measured biomarkers which could accurately predict those dogs' cancers that would and would not respond to doxorubicin chemotherapy. One biomarker (designated 'MEM') showed 100% discriminative capability for predicting clinical response to doxorubicin (area under the ROC curve = 1.00, 95% CI 0.692-1.000), while other biomarkers also showed promising predictive capability. These preliminary findings suggest that ex vivo BDI can accurately predict treatment outcome following doxorubicin chemotherapy in a spontaneous animal cancer model, and is worthy of further investigation as a technology for personalized cancer medicine.

[1]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[2]  Jannik N. Andersen,et al.  Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.

[3]  Lynda M Beaver,et al.  Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008). , 2010, Journal of the American Veterinary Medical Association.

[4]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[5]  J. Modiano,et al.  Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. , 2014, Veterinary immunology and immunopathology.

[6]  M. Miller,et al.  Immunohistochemical Detection of Multiple Myeloma 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Plasmacytoma: Comparison with CD79a and CD20 , 2007, Veterinary pathology.

[7]  D. Knapp,et al.  Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. , 2002, Journal of the American Veterinary Medical Association.

[8]  J. Paul Robinson,et al.  Phenotypic Profiling of Raf Inhibitors and Mitochondrial Toxicity in 3D Tissue Using Biodynamic Imaging , 2014, Journal of biomolecular screening.

[9]  D. Nolte,et al.  Holographic tissue dynamics spectroscopy. , 2011, Journal of biomedical optics.

[10]  D. Nolte,et al.  Time-dependent speckle in holographic optical coherence imaging and the health of tumor tissue. , 2004, Optics letters.

[11]  L. Barber,et al.  Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules. , 2005, Veterinary immunology and immunopathology.

[12]  B. Phillips,et al.  Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog , 2004, Cancer Chemotherapy and Pharmacology.

[13]  David D. Nolte,et al.  Tissue dynamics spectroscopy for phenotypic profiling of drug effects in three-dimensional culture , 2012, Biomedical optics express.

[14]  V. Valli,et al.  Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen , 1987 .

[15]  N. Varki,et al.  Immunophenotypic characterization of chronic lymphoproliferative disorders , 1993 .

[16]  Kwan Jeong,et al.  Volumetric motility-contrast imaging of tissue response to cytoskeletal anti-cancer drugs. , 2007, Optics express.

[17]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[18]  M. Tompkins,et al.  Immunophenotypic characterization of canine lymphoproliferative disorders. , 1997, In vivo.

[19]  J. Sklar,et al.  Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies , 2011, Cancer journal.

[20]  C. Khanna,et al.  Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2010, Veterinary and comparative oncology.

[21]  D. Vail,et al.  Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. , 2000, Journal of veterinary internal medicine.

[22]  M. Miller,et al.  Classification of Canine Malignant Lymphomas According to the World Health Organization Criteria , 2011, Veterinary pathology.

[23]  A. Milligan,et al.  Effect of hyperthermia on normal tissue toxicity and on adriamycin pharmacokinetics in dogs. , 1991, Cancer research.

[24]  D. Matei,et al.  Live tissue viability and chemosensitivity assays using digital holographic motility contrast imaging. , 2013, Applied optics.